NRx Pharmaceuticals (NASDAQ:NRXP) Lifted to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP) to a strong-buy rating in a research report sent to investors on Monday morning, Zacks.com reports.

Other analysts also recently issued research reports about the stock. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. HC Wainwright lifted their price target on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, August 5th.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $1.21 on Monday. The company has a market cap of $12.95 million, a price-to-earnings ratio of -0.39 and a beta of 1.25. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $7.33. The firm has a 50 day moving average of $1.62 and a 200-day moving average of $2.53.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.06. Analysts anticipate that NRx Pharmaceuticals will post -3.25 earnings per share for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.